OMPI

Obagi Medical Products, Inc.

NASDAQ

Add Alert

OMPI

Obagi Medical Products, Inc.

NASDAQ

Add Alert

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating

BooDog

03/21/13 7:29 AM

Post #9

Re: #8: @ospreyeye - OMPI Chart.......Gapper.......huge move today...............$$$

Far out. Gives my little guys some hope smile
congrats!!

ospreyeye

03/20/13 5:52 PM

Post #8

Re: #7: @Edgenation - Ok just sold because of revenue/inventory numbers. I'll

OMPI Chart.......Gapper.......huge move today...............$$$

Edgenation Free

06/18/12 2:34 PM

Post #7

Re: #6: @Edgenation - Haha no, just saying that would be nice!

Ok just sold because of revenue/inventory numbers. I'll be back someday!

Edgenation Free

06/15/12 9:04 PM

Post #6

Re: #5: @mlkrborn - In a week?

Haha no, just saying that would be nice! but intermediate to long term there is a good chance. We shall see!

mlkrborn

06/15/12 5:15 PM

Post #5

Re: #4: @Edgenation - Just got in today at $14.53. Pretty

In a week?
GL
mlkr

Edgenation Free

06/15/12 12:45 PM

Post #4

Re: #3: @mlkrborn - Obagi Medical: Addresses response by Obagi Board of

Just got in today at $14.53. Pretty dead board but the company has great near term potential with a possible buyout still! hopefully this runs to $20 in a week!

mlkrborn

02/17/12 5:50 PM

Post #3

Obagi Medical: Addresses response by Obagi Board of Directors to its letter says 'Voce commends Obagi's appointment of strategic advisors, and further welcomes its public commitment that any acquisition offers' (OMPI) 11.87 : The letter stated "On February 10, 2012, Voce sent a letter to the Obagi Board of Directors criticizing the Board's recent adoption of a poison pill and demanding immediate action to address corporate governance deficiencies and to evaluate strategic alternatives. Voce's letter stated that it believed Obagi has spurned recent overtures to acquire the Company. On February 14, 2012, the Obagi Board responded to Voce's letter. The Board's statement notably did not dispute Voce's claims that the Company had recently received and summarily rebuffed offers to acquire Obagi. In addition, the Obagi Board's response states in part: Voce commends Obagi's appointment of strategic advisors, and further welcomes its public commitment that any acquisition offers from this point forward will be reviewed by these independent advisors. Voce believes that this change in Obagi's posture may invite additional acquisition interest....There is substantial strategic interest in an acquisition of Obagi and broad support for a sale of the Company in both the investment and the analyst community. It behooves the Obagi Board to pursue this potential outcome diligently."

mlkrborn

11/08/09 12:52 PM

Post #2

Too bad no one covered but up since its creation: Chart!
http://stockcharts.com/h-sc/ui?s=ompi&p=D&yr=0&mn=6&dy=0&id=p97690170109

kmx_swing

06/24/08 3:18 PM

Post #1

OMPI board created

Obagi Medical Products, Inc. (OMPI)

Followers	3	Posters	5
Posts (Today)	0	Posts (Total)	9
Created	06/24/08	Type	Free
Moderators

Obagi Medical Products, Inc. , a specialty pharmaceutical company, develops and markets skincare products in the United States and internationally. It develops and commercializes prescription-based, topical skin health systems, which enable physicians to treat a range of skin conditions, including pre-mature aging, photo-damage, hyper-pigmentation, and acne, as well as soft tissue deficits, such as fine lines and wrinkles. The company offers Obagi Nu-Derm System, a prescription-based, topical skin health system on the market that has been shown to enhance the skin's overall health by correcting photo-damage at the cellular level; Obagi-C Rx System, a combination of prescription and OTC drugs and adjunctive cosmetic skin care products to treat skin conditions resulting from sun damage and the oxidative damage of free radicals; and Obagi Professional-C products, a line of proprietary, non-prescription products, which consist of Vitamin C serums used to reduce the appearance of damage to the skin caused by ultraviolet radiation and other environmental influences. It also offers Obagi Condition and Enhance System for use in conjunction with commonly performed cosmetic procedures, including Botox injections; ELASTIderm product line, an eye cream for improving the elasticity and skin tone around the eyes; CLENZIderm product line for addressing acne and skin elasticity; and tretinoin, used for the topical treatment of acne in the United States, and Obagi Blue Peel products, used to aid the physician in the application of skin peeling actives. The company markets its products through its domestic sales force and foreign distribution partners to plastic surgeons, dermatologists, and other physicians that are focused on aesthetic and therapeutic skin care. Obagi Medical Products, Inc. was founded in 1988 and is headquartered in Long Beach, California. Obagi Medical Products, Inc. (OMPI) Full Time Employees: 182 Shares Outstanding5: 22,659,739 Diluted EPS (ttm): 0.52 Operating Cash Flow (ttm): 13,476,000 Revenue (ttm): 101,496,000 Current Assets: 49,959,000 Current Liabilities: 11,922,000 Most Recent Quarter (mrq): March 31,08